Patient: Page 3


  • Quita Highsmith header
    Image attribution tooltip
    Permission granted by Quita Highsmith
    Image attribution tooltip
    Q&A

    The many ‘myths’ of clinical trial diversity, and Genentech’s fight to disrupt them

    Genentech’s chief diversity officer Quita Highsmith is on a crusade to prove that much of what the industry believes about clinical trial diversity is wrong.

    By Dec. 14, 2023
  • COVID pandemic
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    What’s being done to prepare for the next pandemic?

    Will the world be ready when a new outbreak hits? Here’s a look at the efforts to combat emerging viral threats.

    By Kelly Bilodeau • Dec. 13, 2023
  • clinical trial diversity Explore the Trendline
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Clinical trial diversity

    As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.

    By PharmaVoice staff
  • Dr. Julie Gerberding headshot
    Image attribution tooltip
    Permission granted by FNIH
    Image attribution tooltip
    Q&A

    A former CDC head on key R&D areas, public trust and if we learned anything from COVID-19

    Dr. Julie Gerberding, now president and CEO of the Foundation for the National Institutes of Health, shares lessons learned from a long career in academic, public health and industry.

    By Dec. 13, 2023
  • Professional photo of Adam Lenkowsky
    Image attribution tooltip
    Permission granted by Adam Lenkowsky
    Image attribution tooltip
    Q&A

    Bristol Myers’ commercial chief on the industry’s ‘seismic’ changes over 27 years and what’s coming next

    Adam Lenkowsky’s unique vantage point on the major transformations shaping BMS and the industry as a whole.

    By Dec. 12, 2023
  • Chemotherapy cancer
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Oncology drugmakers seek the sweet spot between efficacy and tolerability

    The FDA is now pushing companies to find the optimal dose early in development to minimize harm.

    By Kelly Bilodeau • Dec. 11, 2023
  • A sign showing Gilead's logo
    Image attribution tooltip
    Justin Sullivan via Getty Images
    Image attribution tooltip
    Q&A // First 90 Days

    Patients who hide pills and advocacy offices that could get ‘raided’ — a Gilead leader on navigating global HIV

    Gilead Sciences’ SVP of global patient solutions discusses how she’s managing some of the world’s most complicated health issues and what’s next in HIV innovation.

    By Alexandra Pecci • Dec. 11, 2023
  • A person looking down at a piece of paper while on the phone
    Image attribution tooltip
    damircudic via Getty Images
    Image attribution tooltip
    Sponsored by MedAdvisor Solutions

    Increasing inflation means harder medication decisions for patients

    Explore strategies for life sciences brands to simplify medication journeys for success through MedAdvisor Solutions’ THRIV™ platform, offering up to 5x more lift in adherence.

    Dec. 11, 2023
  • Gene editing
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    The FDA just approved the first CRISPR drug. Here’s what’s next in gene editing.

    A look at the fast-evolving pipeline for gene editing therapies.

    By Dec. 8, 2023
  • Shankar Narayanan, CEO, Real Chemistry
    Image attribution tooltip
    Permission granted by Real Chemistry
    Image attribution tooltip

    Real Chemistry’s CEO on biopharma’s outlook in 2024

    Shankar Narayanan, CEO of marketing consulting firm Real Chemistry, weighs in on where the industry is headed in the New Year.

    By Dec. 7, 2023
  • Closeup shot of an unrecognizable doctor using a digital tablet.
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    The digital therapeutics revolution is here. Will payers play ball?

    Apps, VR and more could play an increasingly vital role in the wider goals of creating value-based treatments — if the industry can get payers to sign on.

    By Kelly Bilodeau • Dec. 5, 2023
  • dollar sign airplane
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    The weight loss market looks unstoppable. How high could it go?

    Market expectations for obesity drugs are soaring and competition is heating up. But hitting the heights will require overcoming payer and other issues.

    By Kelly Bilodeau • Dec. 4, 2023
  • Headshot of Gemma.
    Image attribution tooltip
    Permission granted by AstraZeneca
    Image attribution tooltip
    Sponsored by AstraZeneca

    Transforming blood cancer care to make a difference for patients

    AstraZeneca’s Gemma Satterthwaite talks to the company’s ambition to transform the entire care experience for patients with blood cancers.

    Dec. 4, 2023
  • idea pill
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    3 standout digital innovations in pharma this year

    IDEA Pharma just released its Digital Innovation Index. Here are the top companies they identified and some of the standout advances the industry made.

    By Dec. 1, 2023
  • brain maze
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Octave Bioscience is navigating the Parkinson’s labyrinth with Michael J. Fox’s help

    A grant from the notorious Parkinson’s foundation has sped up Octave’s timeline to further advance biomarker development in the field.

    By Kelly Bilodeau • Nov. 29, 2023
  • Cristina Durán, president, Evinova
    Image attribution tooltip
    Permission granted by AstraZeneca
    Image attribution tooltip
    Q&A

    The head of AstraZeneca’s new digital health business on how the pharma is leveraging tech

    Cristina Durán, formerly AstraZeneca’s chief digital officer of R&D and now head of digital health business Evinova, believes data will help pharma screen and treat patients earlier in their disease.

    By Nov. 28, 2023
  • alcohol bottles illustration
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    As alcohol-related deaths climb, new drugs could curb the urge to drink

    A drug developed by Kinnov Therapeutics halved alcohol consumption in heavy drinkers in a mid-stage study.

    By Kelly Bilodeau • Nov. 27, 2023
  • body muscle
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Biohaven wants to muscle in on the Ozempic craze with a competing class of drugs

    Biohaven and other companies are aiming to develop meds with a different mechanism of action that trim the waistline while building lean tissue.

    By Kelly Bilodeau • Nov. 20, 2023
  • Dr. Paul Moss, deputy head, College of Medical and Dental Sciences, Professor of Haematology, University of Birmingham
    Image attribution tooltip
    Permission granted by AstraZeneca/U. of Birmingham
    Image attribution tooltip
    Q&A

    AstraZeneca showed the pandemic isn’t over for immunocompromised patients. What’s next?

    Dr. Paul Moss, a hematology expert in the U.K., conducted a study with AstraZeneca showing the alarming extent to which immunocompromised patients are burdened with COVID-19.

    By Nov. 16, 2023
  • Genomics DNA
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    The power of genomics-based healthcare remains largely untapped

    23andMe co-founder and CEO Anne Wojcicki discusses ways the industry could integrate genomics into healthcare.

    By Alexandra Pecci • Nov. 15, 2023
  • Denise Bronner headshot
    Image attribution tooltip
    Permission granted by Johnson & Johnson Innovative Medicine
    Image attribution tooltip

    6 ways to improve clinical trial diversity — as shown by J&J

    Johnson & Johnson Innovative Medicine’s director of diversity, equity and inclusion in clinical trials shares key strategies for making DEI work.

    By Alexandra Pecci • Nov. 14, 2023
  • A sickle cell and normal blood cells are seen in red against a blue background in this colorized microscope image.
    Image attribution tooltip

    Janice Haney Carr/CDC/Sickle Cell Foundation of Georgia/AP

    Image attribution tooltip
    Deep Dive

    What if a CRISPR cure isn’t such an easy choice?

    A gene editing therapy developed by Vertex Pharmaceuticals and CRISPR Therapeutics can mute sickle cell disease’s most damaging symptoms. Yet treatment may not be as simple as its dramatic benefit makes it seem.

    By Ned Pagliarulo , Nov. 9, 2023
  • FluMist
    Image attribution tooltip
    Mario Tama / Getty via Getty Images
    Image attribution tooltip

    An at-home flu vaccine? If approved, it could open the door to more DIY options

    A new way to administer vaccines at home could help AstraZeneca reach a wider market for FluMist, the nasal influenza vaccine.

    By Kelly Bilodeau • Nov. 8, 2023
  • Anne Wojcicki red carpet
    Image attribution tooltip
    Dia Dipasupil via Getty Images
    Image attribution tooltip
    Q&A

    23andMe CEO Anne Wojcicki’s vision for changing healthcare as a ‘full-fledged biotech’

    23andMe always had bigger aims than at-home genetics testing. In this in-depth interview, the company’s founder explains its foray into pharma, drug R&D, solving cold cases and more.  

    By Alexandra Pecci • Nov. 7, 2023
  • Arthur Caplan, professor of bioethics and founding head of the Division of Medical Ethics, NYU’s Grossman School of Medicine
    Image attribution tooltip
    Permission granted by NYU
    Image attribution tooltip
    Opinion

    The thorniest questions facing pharma, according to a leading bioethicist

    Bioethics guru Arthur Caplan of NYU gives his outspoken and frank opinion on the industry’s minefield of ethical challenges.

    By Nov. 6, 2023
  • Entrepreneur heeader
    Image attribution tooltip

    Photo illustration: Industry Dive; Getty Images

    Image attribution tooltip
    PharmaVoice 100

    PharmaVoice 100s: Entrepreneurs

    From biotech startups to a services agency, these entrepreneurs are hedging their bets to offer innovative approaches in patient care.

    By Nov. 3, 2023